Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians

A new review article led by Dr. John R. P. Tesser, MD, FACP, FACR, MACR, and AARA Clinical Research offers key insights for U.S. clinicians on switching from reference product adalimumab to its biosimilars based on data from outside the U.S. The review finds that switching to adalimumab biosimilars is generally safe and effective across multiple chronic inflammatory diseases. While most patients maintain stable outcomes after switching, the study highlights the importance of patient education, physician guidance, and supportive policies. The findings support broader use of biosimilars to reduce costs and expand access to care in the U.S. healthcare system.

Read the full review article here:
https://link.springer.com/article/10.1007/s40259-025-00719-z